Literature DB >> 28802855

Antifungal resistance in mucorales.

E Dannaoui1.   

Abstract

The order Mucorales, which includes the agents of mucormycosis, comprises a large number of species. These fungi are characterised by high-level resistance to most currently available antifungal drugs. Standardised antifungal susceptibility testing methods are now available, allowing a better understanding of the in vitro activity of antifungal drugs against members of Mucorales. Such tests have made apparent that antifungal susceptibility within this group may be species-specific. Experimental animal models of mucormycosis have also been developed and are of great importance in bridging the gap between in vitro results and clinical trials. Amphotericin B, posaconazole and isavuconazole are currently the most active agents against Mucorales; however, their activity remains suboptimal and new therapeutic strategies are needed. Combination therapy could be a promising approach to overcome resistance, but further studies are required to confirm its benefits and safety for patients.
Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Animal models; Antifungals; Combination; Mucorales; Resistance; Susceptibility testing

Mesh:

Substances:

Year:  2017        PMID: 28802855     DOI: 10.1016/j.ijantimicag.2017.08.010

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  39 in total

1.  Evaluation of the Gradient Concentration Strip Method for Antifungal Susceptibility Testing of Isavuconazole and Comparators for Mucorales Species.

Authors:  Pauline Vidal; Patrick Schwarz; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

2.  In Vitro Activity of Combinations of Zinc Chelators with Amphotericin B and Posaconazole against Six Mucorales Species.

Authors:  Florencia Leonardelli; Daiana Macedo; Catiana Dudiuk; Laura Theill; Matias S Cabeza; Soledad Gamarra; Guillermo Garcia-Effron
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

3.  A Revised Species Concept for Opportunistic Mucor Species Reveals Species-Specific Antifungal Susceptibility Profiles.

Authors:  Lysett Wagner; Sybren de Hoog; Ana Alastruey-Izquierdo; Kerstin Voigt; Oliver Kurzai; Grit Walther
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 4.  Current Treatment Options for COVID-19 Associated Mucormycosis: Present Status and Future Perspectives.

Authors:  Yasasve Madhavan; Kadambari Vijay Sai; Dilip Kumar Shanmugam; Aashabharathi Manimaran; Karthigadevi Guruviah; Yugal Kishore Mohanta; Divyambika Catakapatri Venugopal; Tapan Kumar Mohanta; Nanaocha Sharma; Saravanan Muthupandian
Journal:  J Clin Med       Date:  2022-06-23       Impact factor: 4.964

Review 5.  Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients.

Authors:  Kevin J Downes; Brian T Fisher; Nicole R Zane
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

6.  Molecular Confirmation of the Linkage between the Rhizopus oryzae CYP51A Gene Coding Region and Its Intrinsic Voriconazole and Fluconazole Resistance.

Authors:  Daiana Macedo; Florencia Leonardelli; Catiana Dudiuk; Laura Theill; Matías S Cabeza; Soledad Gamarra; Guillermo Garcia-Effron
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

7.  Cathelicidin-inspired antimicrobial peptides as novel antifungal compounds.

Authors:  Martin van Eijk; Stephanie Boerefijn; Lida Cen; Marisela Rosa; Marnix J H Morren; Cornelis K van der Ent; Bart Kraak; Jan Dijksterhuis; Ivan D Valdes; Henk P Haagsman; Hans de Cock
Journal:  Med Mycol       Date:  2020-11-10       Impact factor: 4.076

8.  Combat trauma-related invasive fungal wound infections.

Authors:  David R Tribble; Anuradha Ganesan; Carlos J Rodriguez
Journal:  Curr Fungal Infect Rep       Date:  2020-04-16

9.  Mucormycosis: Literature review and retrospective report of 15 cases from Portugal.

Authors:  Beatriz Prista Leão; Isabel Abreu; Ana Cláudia Carvalho; António Sarmento; Lurdes Santos
Journal:  Curr Med Mycol       Date:  2020-12

10.  In Vitro Activity of Novel Antifungal Olorofim against Filamentous Fungi and Comparison to Eight Other Antifungal Agents.

Authors:  Ourania Georgacopoulos; Natalie S Nunnally; Eric M Ransom; Derek Law; Mike Birch; Shawn R Lockhart; Elizabeth L Berkow
Journal:  J Fungi (Basel)       Date:  2021-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.